Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

被引：11
|
作者：
Tettero, Jesse M. [1 ,2 ]
Ngai, Lok Lam [1 ,2 ]
Bachas, Costa [1 ,2 ]
Breems, Dimitri A. [3 ]
Fischer, Thomas [4 ]
Gjertsen, Bjorn T. [5 ]
Gradowska, Patrycja [6 ]
Griskevicius, Laimonas [7 ,8 ]
Janssen, Jeroen J. W. M. [1 ,2 ]
Juliusson, Gunnar [9 ]
Maertens, Johan [10 ]
Manz, Markus G. [11 ]
Pabst, Thomas [12 ,13 ,14 ]
Passweg, Jakob [12 ,14 ]
Porkka, Kimmo [15 ]
Valk, Peter J. M. [16 ,17 ]
Loewenberg, Bob [16 ,17 ]
Ossenkoppele, Gert J. [1 ,2 ]
Cloos, Jacqueline [1 ,2 ]
机构：
[1] Univ Amsterdam, Locat VUmc, Med Ctr, Amsterdam, Netherlands
[2] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands
[3] Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
[4] Otto von Guericke Univ Hosp Magdeburg, Magdeburg, Germany
[5] Haukeland Hosp, Bergen, Norway
[6] Erasmus MC Canc Inst, Data Ctr, Dutch Belgian Hemato Oncol Cooperat Grp, Rotterdam, Netherlands
[7] Vilnius Univ Hosp, Santaros Klin, Vilnius, Lithuania
[8] Vilnius Univ, Vilnius, Lithuania
[9] Skanes Univ Hosp, Lund, Sweden
[10] Univ Hosp Gasthuisberg, Leuven, Belgium
[11] Univ Hosp, Zurich, Switzerland
[12] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland
[13] Inselspital Bern, Dept Med Oncol, Bern, Switzerland
[14] Univ Hosp, Basel, Switzerland
[15] Helsinki Univ Hosp, Canc Ctr, Helsinki, Finland
[16] Erasmus Univ, Med Ctr MC, Rotterdam, Netherlands
[17] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
HAEMATOLOGICA | 2023年 / 108卷 / 10期
关键词：
ADULTS; AML; YOUNGER;
D O I：
10.3324/haematol.2022.282639
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2794 / 2798
页数：5
相关论文
共 50 条
  • [21] Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia
    Wang, Lulu
    Chen, Yuxiu
    Zang, Mengtong
    Zhou, Jianying
    Xiao, Mengyu
    Fu, Haixia
    Mo, Xiaodong
    Wang, Fengrong
    Han, Wei
    Zhang, Yuanyuan
    Yan, Chenhua
    Wang, Zhidong
    Han, Tingting
    Lv, Meng
    Chen, Huan
    Chen, Yuhong
    Chen, Yao
    Wang, Jingzhi
    Wang, Yu
    Xu, Lanping
    Liu, Kaiyan
    Huang, Xiaojun
    Zhang, Xiaohui
    CANCER, 2025, 131 (02)
  • [22] Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing
    Ahn, Jae-Sook
    Kim, TaeHyung
    Jung, Sung-Hoon
    Ahn, Seo-Yeon
    Jung, Seung-Yeon
    Song, Ga-Young
    Kim, Mihee
    Yang, Deok-Hwan
    Lee, Je-Jung
    Choi, SeungHyun
    Lee, Ja-Yeon
    Park, Seong-Kyu
    Moon, Joon Ho
    Lee, Hui Young
    Kim, Kyoung Ha
    Cai, Yu
    Yi, Seong Yoon
    Novitzky-Basso, Igor
    Zhang, Zhaolei
    Kim, Hyeoung-Joon
    Kim, Dennis Dong Hwan
    BONE MARROW TRANSPLANTATION, 2021, 56 (05) : 1159 - 1170
  • [23] Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings
    Ma, Yan-Ru
    Xu, Lan-Ping
    Zhang, Xiao-Hui
    Liu, Kai-Yan
    Chang, Ying-Jun
    Lv, Meng
    Yan, Chen-Hua
    Chen, Yu-Hong
    Han, Wei
    Wang, Feng-Rong
    Mo, Xiao-Dong
    Huang, Xiao-Jun
    Wang, Yu
    ANNALS OF HEMATOLOGY, 2021, 100 (02) : 555 - 562
  • [24] Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease
    Blackmon, Amanda
    Afkhami, Michelle
    Yang, Dongyun
    Mokhtari, Sally
    Samara, Yazeed
    Pourhassan, Hoda
    Ball, Brian
    Salhotra, Amandeep
    Agrawal, Vaibhav
    Sandhu, Karamjeet
    Desai, Amrita
    Otoukesh, Salman
    Arslan, Shukaib
    Amanam, Idoroenyi
    Koller, Paul
    Tinajero, Jose
    Aribi, Ahmed
    Aldoss, Ibrahim
    Becker, Pamela
    Artz, Andy
    Ali, Haris
    Stein, Anthony
    Smith, Eileen
    Pullarkat, Vinod
    Forman, Stephen J.
    Marcucci, Guido
    Nakamura, Ryotaro
    Al Malki, Monzr M.
    BONE MARROW TRANSPLANTATION, 2025, 60 (02) : 165 - 174
  • [25] Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia
    Shimomura, Yoshimitsu
    Hara, Masahiko
    Maruoka, Hayato
    Yabushita, Tomohiro
    Ishikawa, Takayuki
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 745 - 748
  • [26] Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
    Platzbecker, Uwe
    Middeke, Jan Moritz
    Sockel, Katja
    Herbst, Regina
    Wolf, Dominik
    Baldus, Claudia D.
    Oelschlagel, Uta
    Mutherig, Anke
    Fransecky, Lars
    Noppeney, Richard
    Bug, Gesine
    Goetze, Katharina S.
    Kraemer, Alwin
    Bochtler, Tilmann
    Stelljes, Matthias
    Groth, Christoph
    Schubert, Antje
    Mende, Marika
    Stoelzel, Friedrich
    Borkmann, Christin
    Kubasch, Anne Sophie
    von Bonin, Malte
    Serve, Hubert
    Haenel, Mathias
    Duehrsen, Ulrich
    Schetelig, Johannes
    Roellig, Christoph
    Kramer, Michael
    Ehninger, Gerhard
    Bornhaeuser, Martin
    Thiede, Christian
    LANCET ONCOLOGY, 2018, 19 (12) : 1668 - 1679
  • [27] Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
    Freeman, Sylvie D.
    Hills, Robert K.
    Virgo, Paul
    Khan, Naeem
    Couzens, Steve
    Dillon, Richard
    Gilkes, Amanda
    Upton, Laura
    Nielsen, Ove Juul
    Cavenagh, James D.
    Jones, Gail
    Khwaja, Asim
    Cahalin, Paul
    Thomas, Ian
    Grimwade, David
    Burnett, Alan K.
    Russell, Nigel H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15) : 1486 - +
  • [28] Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission
    Versluis, Jurjen
    Kalin, Burak
    Zeijlemaker, Wendelien
    Passweg, Jakob
    Graux, Carlos
    Manz, Markus G.
    Vekemans, Marie-Christiane
    Biemond, Bart J.
    Legdeur, Marie-Cecile J. C.
    Kooy, Marinus van Marwijk
    de Weerdt, Okke
    Wijermans, Pierre W.
    Hoogendoorn, Mels
    Bargetzi, Mario J.
    Kuball, Juergen
    Schouten, Harry C.
    van der Velden, Vincent H. J.
    Janssen, Jeroen J. W. M.
    Pabst, Thomas
    Lowenberg, Bob
    Jongen-Lavrencic, Mojca
    Schuurhuis, Gerrit Jan
    Ossenkoppele, Gert
    Cornelissen, Jan J.
    JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 13
  • [29] Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT
    Chen, Jia
    Labopin, Myriam
    Pabst, Thomas
    Zhang, Xi
    Jiang, Erlie
    Tucci, Alessandra
    Cornelissen, Jan
    Meijer, Ellen
    Khevelidze, Irma
    Polge, Emmanuelle
    Wu, Depei
    Mohty, Mohamad
    Gorin, Norbert-Claude
    BONE MARROW TRANSPLANTATION, 2023, 58 (12) : 1322 - 1330
  • [30] Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia
    Hoffmann, Alexander P.
    Besch, Ashley L.
    Othus, Megan
    Morsink, Linde M.
    Wood, Brent L.
    Mielcarek, Marco
    Estey, Elihu H.
    Appelbaum, Frederick R.
    Walter, Roland B.
    BONE MARROW TRANSPLANTATION, 2020, 55 (03) : 669 - 672
12345